Enhancing Nrf2 pathway by disruption of Keap1 in myeloid leukocytes protects against sepsis
- PMID: 21799073
- PMCID: PMC3208662
- DOI: 10.1164/rccm.201102-0271OC
Enhancing Nrf2 pathway by disruption of Keap1 in myeloid leukocytes protects against sepsis
Abstract
Rationale: Sepsis syndrome is characterized by inappropriate amplified systemic inflammatory response and bacteremia that promote multiorgan failure and mortality. Nuclear factor-erythroid 2 p45-related factor 2 (Nrf2) regulates a pleiotropic cytoprotective defense program including antioxidants and protects against several inflammatory disorders by inhibiting oxidative tissue injuries. However, the role of enhanced Nrf2 activity in modulating innate immune responses to microbial infection and pathogenesis of sepsis is unclear.
Objectives: To determine whether Nrf2 in myeloid leukocytes alters inflammatory response and protects against sepsis.
Methods: Mice with deletion of Nrf2 or kelch-like ECH-associated protein (Keap1) in myeloid leukocyte cells and respective floxed controls were subjected to cecal ligation and puncture-induced sepsis and were assessed for survival, organ injury, systemic inflammation, and bacteremia. Using LPS-stimulated peritoneal macrophages, Toll-like receptor (TLR) 4 surface trafficking and downstream signaling events were analyzed.
Measurements and main results: Mortality, organ injury, circulating levels of inflammatory mediators, and bacteremia were markedly reduced in LysM-Keap1(-/-) compared with respective floxed controls (Keap1(f/f) or Nrf2(f/f)) and significantly elevated in LysM-Nrf2(-/-) mice after cecal ligation and puncture. Peritoneal macrophages from septic LysM-Keap1(-/-) mice showed a greater bacterial phagocytic activity compared with LysM-Nrf2(-/-) and floxed controls. LPS stimulation resulted in greater reactive oxygen species-induced cell surface transport of TLR4 from trans-Golgi network and subsequent TLR4 downstream signaling (recruitment of MYD88 and TRIF, phosphorylation of IkB and IRF3, and cytokine expression) in macrophages of LysM-Nrf2(-/-) compared with LysM-Keap1(-/-) mice and floxed controls.
Conclusions: Our study shows that Nrf2 acts as a critical immunomodulator in leukocytes, controls host inflammatory response to bacterial infection, and protects against sepsis.
Figures
References
-
- Riedemann NC, Guo RF, Ward PA. Novel strategies for the treatment of sepsis. Nat Med 2003;9:517–524 - PubMed
-
- Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A, Sicignano A, Palazzo M, Moreno R, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002;28:108–121 - PubMed
-
- Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303–1310 - PubMed
-
- Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez, Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699–709 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- 5P50ES015903/ES/NIEHS NIH HHS/United States
- R01 GM079239/GM/NIGMS NIH HHS/United States
- P50 ES015903/ES/NIEHS NIH HHS/United States
- R01 ES011863/ES/NIEHS NIH HHS/United States
- R01 HL081205/HL/NHLBI NIH HHS/United States
- P50 HL084945/HL/NHLBI NIH HHS/United States
- P50HL084945/HL/NHLBI NIH HHS/United States
- HL081205/HL/NHLBI NIH HHS/United States
- R01 HL066109/HL/NHLBI NIH HHS/United States
- GM079239/GM/NIGMS NIH HHS/United States
- P30 ES003819/ES/NIEHS NIH HHS/United States
- HL66109/HL/NHLBI NIH HHS/United States
- R01 GM050401/GM/NIGMS NIH HHS/United States
- R56 ES011863/ES/NIEHS NIH HHS/United States
- GM50401/GM/NIGMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
